Increased vasoconstrictor response to noradrenaline in femoral vascular bed of diabetic dogs. Is thromboxane A2 involved?
OBJECTIVE
The aim was to determine the role of cyclo-oxygenase products in the vasoconstrictor response of femoral arterial bed to noradrenaline and to analyse the role of vascular adrenoceptors in the synthesis of cyclo-oxygenase products.


METHODS
The influence of intra-arterially injected cyclo-oxygenase inhibitors indomethacin and acetylsalicylic acid on alterations in conductance of femoral arterial bed induced by noradrenaline was compared in metabolically healthy and alloxan diabetic dogs. PGI2 and TXA2 synthesising ability of isolated femoral arterial rings was measured with and without inhibition of alpha adrenoceptors by phentolamine.


METHODS
18 metabolically healthy and 18 alloxan (560 mumol.kg-1) diabetic dogs of either sex, weight 16-28 kg, were studied.


RESULTS
Noradrenaline produced greater (p less than 0.01) pressor effects in the femoral arterial bed of alloxan diabetic dogs than in the hind limb of control animals. Blockade of cyclo-oxygenase either by indomethacin 10 mumol.kg-1 or by acetylsalicylic acid 140 mumol.kg-1 markedly reduced the response to noradrenaline in alloxan treated animals, but not in controls, thereby eliminating the different responsiveness of the two groups. Femoral arterial rings from diabetic animals synthesised similar amounts of PGI2 as control rings but formed more TXA2 (p less than 0.05). Phentolamine pretreatment (5 mumol.litre-1) markedly reduced the production of TXA2, but not of PGI2, in diabetic vessels.


CONCLUSIONS
The results show an increased release of TXA2 by isolated diabetic femoral arteries. It is therefore suggested that an alpha adrenoceptor mediated increase in TXA2 biosynthesis may play a part in the vascular hyperreactivity of the diabetic femoral arterial bed.
Koltai
M Z
MZ
National Institute of Cardiology, Budapest, Hungary.
Rösen
P
P
Ballagi-Pordány
G
G
Hadházy
P
P
Pogátsa
G
G
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000503:physiopathology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000096:biosynthesis; D005260:Female; D005268:Femoral Vein / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology*; D009924:Organ Culture Techniques; D010646:Phentolamine / Q000494:pharmacology; D013928:Thromboxane A2 / Q000096:biosynthesis*; D014661:Vasoconstriction / Q000187:drug effects*
D016861:Cyclooxygenase Inhibitors; D013928:Thromboxane A2; D011464:Epoprostenol; D001241:Aspirin; D009638:Norepinephrine; D007213:Indomethacin; D010646:Phentolamine